Drugs / CHM-2101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06055439 | May 2024 → May 2026 overdue | colorectal cancer, gastric cancer, neuroendocrine neoplasm | Chimeric Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHM-2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06055439 ↗ |
| Modality | Cell therapy | “an autologous CDH17 CAR T-cell therapy” NCT06055439 ↗ |
| Route | Intravenous | “participants will receive a single dose of IV CHM-2101” NCT06055439 ↗ |
| Target | CDH17 | “Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells” NCT06055439 ↗ |